Jorge Jonathan Nué Martinez

Prof. Dr. Jorge Jonathan Nué Martinez

orcid

Research Focus & Metrics

Representative Publications

View All Publications
16 June 2017 in Nucleic Acids Research
Verified
Journal Article
Open access
PDF file
CMCinthia R. Millan
Cinthia R. Millan
FAFrancisco J. Acosta-Reyes
Francisco J. Acosta-Reyes
LLLaura Lagartera
Laura Lagartera
GEGodwin Unekwuojo Ebiloma
Godwin Unekwuojo Ebiloma
LLLeandro Lemgruber
Leandro Lemgruber
JCJ. Lourdes Campos
J. Lourdes Campos
Trypanosoma brucei, the causative agent of sleeping sickness (Human African Trypanosomiasis, HAT), contains a kinetoplast with the mitochondrial DNA (kDNA), comprising of >70% AT base pairs. This has prompted studies of drugs interacting with AT-rich DNA, such as the N-phenylbenzamide bis(2-aminoimidazoline) derivatives 1 [4-((4,5-dihydro-1H-imidazol-2-yl)amino)-N-(4-((4,5-dihydro-1H-imidazol-2-yl)amino)phenyl)benzamide dihydrochloride] and 2 [N-(3-chloro-4-((4,5-dihydro-1H-imidazol-2-yl)amino)phenyl)-4-((4,5-dihydro-1H-imidazol-2-yl)amino)benzamide] as potential drugs for HAT. Both compounds show in vitro effects against T. brucei and in vivo curative activity in a mouse model of HAT. The main objective was to identify their cellular target inside the parasite. We were able to demonstrate that the compounds have a clear effect on the S-phase of T. brucei cell cycle by inflicting specific damage on the kinetoplast. Surface plasmon resonance (SPR)–biosensor experiments show that the drug can displace HMG box-containing proteins essential for kDNA function from their kDNA binding sites. The crystal structure of the complex of the oligonucleotide d[AAATTT]2 with compound 1 solved at 1.25 Å (PDB-ID: 5LIT) shows that the drug covers the minor groove of DNA, displaces bound water and interacts with neighbouring DNA molecules as a cross-linking agent. We conclude that 1 and 2 are powerful trypanocides that act directly on the kinetoplast, a structure unique to the order Kinetoplastida.

1 August 2015 in European Journal of Medicinal Chemistry
Verified
Journal Article
Closed access
CMCarlos H. Ríos Martínez
Carlos H. Ríos Martínez
JMJorge Jonathan Nué Martinez
Jorge Jonathan Nué Martinez
GEGodwin Unekwuojo Ebiloma
Godwin Unekwuojo Ebiloma
HKHarry De Koning
Harry De Koning
Ibon AlkortaIbon Alkorta
Ibon Alkorta
Christophe DardonvilleChristophe Dardonville
Christophe Dardonville

26 October 2017 in Current Medicinal Chemistry
Verified
Journal Article
Closed access
PDF file
Christophe DardonvilleChristophe Dardonville
Christophe Dardonville
JMJorge Jonathan Nué Martinez
Jorge Jonathan Nué Martinez
Background: Parasitic diseases caused by protozoan parasites of the genus Trypanosoma and Plasmodium cause some of the deadliest and disabling human infections in tropical and subtropical areas. Diphenyl-based bis(2-phenylimino)imidazolidines and bisguanidines are extremely potent antiparasitic agents against Trypanosoma brucei (etiological agent of African trypanosomiasis) and Plasmodium falciparum (etiological agent of severe malaria). Many of these compounds are also curative in mouse models of stage 1 African trypanosomiasis representing promising leads for the development of antitrypanosomal drugs. In addition, different classes of bis(2-iminoimidazolidines) and bisguanidines have been shown to have antimicrobial activity against other pathogens (e.g. bacteria, fungi, parasitic worms). Due to their structural and physicochemical properties, these dibasic compounds, which are dications at physiological pH, are prone to bind to the minor groove of DNA at AT-rich sites. In several cases, such interaction is thought to be responsible for their antimicrobial activity. Results: In this review, we give a comprehensive view of the synthetic methods used to introduce the 2-aminoimidazoline scaffold in a molecule. Synthetic routes that give access to these cyclic guanidines (i.e. unsubstituted, 1-, 4-, and 5-substituted 2-aminoimidazolines) are detailed. The in vitro and in vivo antiprotozoal activity of bis(2-aminoimidazolines) and bisguanidines against kinetoplastid parasites (T. brucei, T. cruzi, Leishmania), Plasmodium spp. and other pathogens (e.g. ESKAPE bacteria, Candida spp., M. tuberculosis, E. multilocularia) is also reviewed. Finally, the targets that are involved in the antimicrobial activity (e.g. DNA) or other biological activities (e.g. α-adrenergic receptors, imidazoline binding sites, kinases) of this class of dicationic compounds are discussed.

19 February 2025 in ACS Omega
Verified
Journal Article
Open access
JMJorge Jonathan Nué Martinez
Jorge Jonathan Nué Martinez
MLMarta Leo-Barriga
Marta Leo-Barriga
Fernando HerranzFernando Herranz
Fernando Herranz
ZKZisis Koutsogiannis
Zisis Koutsogiannis
PDPaul Denny
Paul Denny
AGAna González-Paredes
Ana González-Paredes
Two types of nanostructured lipid carrier (NLC) formulations of the antileishmanial DNA minor groove binding compound 4-(picolinimidamido)-N-(4-(picolinimidamido)phenyl)benzamide (1) were synthesized by the microemulsion method to evaluate their potential as a delivery system to intracellular forms of the Leishmania parasite. Compound 1-loaded NLC formulations, functionalized with folic acid (FA) or not, showed good colloidal stability both during storage and after dilution in biologically relevant media. The drug release, which was not pH dependent, occurred efficiently at 37 °C. Compound 1 and its NLC formulations displayed a good selectivity index (SI > 40) and were active in the submicromolar range against promastigotes and metacyclic promastigotes of Leishmania major and in the low micromolar range (∼2 μM) against intramacrophage amastigotes. However, they were inactive against Leishmania mexicana. This proof-of-concept study showed that compound 1 could be loaded effectively in NLC and FA-coated NLC whose size and anionic nature (i.e., FA-NLC) are favorable for uptake into macrophages. NLC functionalization with FA had a beneficial effect on the antileishmanial activity of 1 compared with noncoated NLC formulations, which resulted in an increase in selectivity toward the parasite.

12 December 2023 in Beilstein Journal of Organic Chemistry
Verified
Journal Article
Open access
PDF file
MLM. Ángeles Gutiérrez López
M. Ángeles Gutiérrez López
MTMei-Ling Tan
Mei-Ling Tan
GRGiacomo Renno
Giacomo Renno
AJAugustina Jozeliūnaitė
Augustina Jozeliūnaitė
JMJorge Jonathan Nué Martinez
Jorge Jonathan Nué Martinez
SMStefan Matile
Stefan Matile
Anion–π catalysis, introduced in 2013, stands for the stabilization of anionic transition states on π-acidic aromatic surfaces. Anion–π catalysis on carbon allotropes is particularly attractive because high polarizability promises access to really strong anion–π interactions. With these expectations, anion–π catalysis on fullerenes has been introduced in 2017, followed by carbon nanotubes in 2019. Consistent with expectations from theory, anion–π catalysis on carbon allotropes generally increases with polarizability. Realized examples reach from enolate addition chemistry to asymmetric Diels–Alder reactions and autocatalytic ether cyclizations. Currently, anion–π catalysis on carbon allotropes gains momentum because the combination with electric-field-assisted catalysis promises transformative impact on organic synthesis.

26 June 2025 in Pharmaceutics
Verified
Journal Article
Open access
PDF file
ACAlmudena Laguna Castro
Almudena Laguna Castro
BABorja Martínez Alonso
Borja Martínez Alonso
VGVíctor Guarnizo-Herrero
Víctor Guarnizo-Herrero
JMJorge Jonathan Nué Martinez
Jorge Jonathan Nué Martinez
Christophe DardonvilleChristophe Dardonville
Christophe Dardonville
CSCarlos Torrado Salmerón
Carlos Torrado Salmerón
Background/Objectives: Currently there are very few effective oral antileishmanial treatments. In this study we evaluated a new bis(pyridine-2-carboxamidine) antileishmanial drug (JNII40_base) and its hydrochloride salt (JNII40_HCl). Methods: The characterization studies performed allowed us to determine the crystallinity, hydration water, and presence of hydrogen bonds in these drugs. Different dissolution methods were employed to predict intestinal absorption. A high-performance liquid chromatography–mass spectrophotometry (HPLC-MS/MS) method was developed for the determination of JNII40 in plasma. Results: Pharmacokinetic studies in rats of JNII40_base at 100 and 20 mg/kg, and JNII40_HCl at 20 mg/kg, showed a non-linear pharmacokinetic at high doses. An innovative biorelevant medium of phosphate buffer pH 6.8 with polysorbate 80 at 0.6% (w/v) showed high concentration values for JNII40_base at 30 min, which predicts good intestinal absorption. These results were consistent with the bioavailability data, which exhibited a significant (p < 0.05) increase in maximum plasma concentration (Cmax) and a slight delay in time to maximum (Tmax) compared to JNII40_HCl. Furthermore, the sustained release of JNII40_base in this biorelevant media was related to high plasma concentration values at 24 h (C24h) observed in bioavailability studies. These plasma concentrations of JNII40_base were above the half-maximal inhibitory concentration (IC50) against promastigote and amastigote forms of Leishmania donovani, which is indicative of effectiveness and should reduce the occurrence of drug resistance during treatments. Conclusions: The bioavailability and pharmacokinetic data support the consideration of this drug for further in vivo studies as an oral antileishmanial treatment.